Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Rickels, K. Articles by Sheehan, D. Search for Related Content PubMed Citation Articles by Rickels, K. Articles by Sheehan, D. Anxiety Disorders (General) Antidepressants

Paroxetine Treatment of Generalized Anxiety Disorder: A Double-Blind, Placebo-Controlled Study

OBJECTIVE: This study assessed the efficacy of two fixed doses of paroxetine in the treatment of generalized anxiety disorder. METHOD: Outpatients (N=566) with generalized anxiety disorder and no other axis I disorder were eligible if they scored 20 on the Hamilton Rating Scale for Anxiety (with a score of 2 or higher on the anxious mood and tension items). Following a 1-week placebo run-in phase, patients were randomly assigned to 8 weeks of treatment with paroxetine, 20 or 40 mg/day, or placebo. The primary outcome measure was the change from baseline in total score on the Hamilton anxiety scale. Response was defined as a rating of "very much improved" or "much improved" on the Clinical Global Impression global improvement measure; remission was defined as a Hamilton anxiety scale score 7. Change in functional impairment was measured with the Sheehan Disability Scale. RESULTS: At 8 weeks, reductions in total score on the Hamilton anxiety scale were significantly greater for both paroxetine groups. Response was achieved by 62% and 68% of the patients receiving 20 and 40 mg of paroxetine, respectively, compared with a 46% response rate in the placebo group. Remission was achieved by 30% and 36% of patients in the 20- and 40-mg paroxetine groups, respectively, compared with 20% given placebo. For all three domains of the Sheehan Disability Scale, significantly greater improvement was seen with paroxetine than placebo. Both doses of paroxetine were well tolerated. CONCLUSIONS: This study demonstrates that paroxetine is an efficacious and well-tolerated treatment for generalized anxiety disorder.

This article has been cited by other articles:

				D Nutt, C Allgulander, Y Lecrubier, T Peters, and U Wittchen Establishing non-inferiority in treatment trials in psychiatry -- guidelines from an Expert Consensus Meeting J Psychopharmacol, June 1, 2008; 22(4): 409 - 416. [Abstract] [PDF]

				R. B. Hidalgo, L. A. Tupler, and J. R. T. Davidson An effect-size analysis of pharmacologic treatments for generalized anxiety disorder J Psychopharmacol, November 1, 2007; 21(8): 864 - 872. [Abstract] [PDF]

				M. A. Rynn, M. A. Riddle, P. P. Yeung, and N. R. Kunz Efficacy and Safety of Extended-Release Venlafaxine in the Treatment of Generalized Anxiety Disorder in Children and Adolescents: Two Placebo-Controlled Trials Am J Psychiatry, February 1, 2007; 164(2): 290 - 300. [Abstract] [Full Text] [PDF]

				D. S. Baldwin, A. K. T. Huusom, and E. Maehlum Escitalopram and paroxetine in the treatment of generalised anxiety disorder: Randomised, placebo-controlled, double-blind study The British Journal of Psychiatry, September 1, 2006; 189(3): 264 - 272. [Abstract] [Full Text] [PDF]

				E. Abramovich Application of CBT in an Inpatient Setting: Case Illustration of an Adult Male With Anxiety, Depression, and Axis II Symptoms Clinical Case Studies, August 1, 2006; 5(4): 305 - 330. [Abstract] [PDF]

				D. S. Baldwin, I. M. Anderson, D. J. Nutt, B. Bandelow, A. Bond, J. R. T. Davidson, J. A. den Boer, N. A. Fineberg, M. Knapp, J. Scott, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology J Psychopharmacol, November 1, 2005; 19(6): 567 - 596. [Abstract] [PDF]

				K. Rickels, M. H. Pollack, D. E. Feltner, R. B. Lydiard, D. L. Zimbroff, R. J. Bielski, K. Tobias, J. D. Brock, G. L. Zornberg, and A. C. Pande Pregabalin for Treatment of Generalized Anxiety Disorder: A 4-Week, Multicenter, Double-blind, Placebo-Controlled Trial of Pregabalin and Alprazolam Arch Gen Psychiatry, September 1, 2005; 62(9): 1022 - 1030. [Abstract] [Full Text] [PDF]

				W. Jiang, M. Kuchibhatla, M. S. Cuffe, E. J. Christopher, J. D. Alexander, G. L. Clary, M. A. Blazing, L. H. Gaulden, R. M. Califf, R. R. Krishnan, et al. Prognostic Value of Anxiety and Depression in Patients With Chronic Heart Failure Circulation, November 30, 2004; 110(22): 3452 - 3456. [Abstract] [Full Text] [PDF]

				C. Allgulander, A. A. Dahl, C. Austin, P. L.P. Morris, J. A. Sogaard, R. Fayyad, S. P. Kutcher, and C. M. Clary Efficacy of Sertraline in a 12-Week Trial for Generalized Anxiety Disorder Am J Psychiatry, September 1, 2004; 161(9): 1642 - 1649. [Abstract] [Full Text] [PDF]

				G. Fricchione Generalized Anxiety Disorder N. Engl. J. Med., August 12, 2004; 351(7): 675 - 682. [Full Text] [PDF]

				Paroxetine for Generalized Anxiety Journal Watch Psychiatry, June 4, 2003; 2003(604): 9 - 9. [Full Text]

				Paroxetine for Generalized Anxiety Journal Watch (General), April 29, 2003; 2003(429): 4 - 4. [Full Text]

Get information about faster international access.

Privacy Policy

Copyright © 2003 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us